Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Mind Medicine a Buy?

TheMotleyFool

0 0

The market for psychedelic drugs could be worth $10.8 billion by 2027, growing at an annual rate of 12.4% until then, according to ResearchAndMarkets.com. It's an exciting new sector to invest in, with many people comparing it to the early days of the cannabis industry, and Mind Medicine (NASDAQ: MNMD) is one investable company at the forefront.

The biotech, also known as MindMed, is in early stages of working on multiple drugs that could potentially hit the psychedelics market. But with no revenue, mounting losses, and a ton of risk, should investors take a chance on the stock?

Image source: Getty Images.

Source Fool.com

Like: 0

MNMD

Share